MONTREAL, December 14th, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting
a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) coinfection, announces the publication of an invited review article by its CSO, Dr. Andrew Vaillant entitled
“HBsAg, Subviral Particles, and Their Clearance in Establishing a Functional Cure of Chronic B Virus
Infection” in the journal ACS Infectious Diseases here.
This review includes an update on the following:
- The current understanding of the structure and function of HBsAg and subviral particles (SVP),
which constitute almost all HBsAg in the blood of patients with HBV infection.
- The role of SVP in maintaining chronic infection by suppressing the immune response essential to
restoring functional cure.
- Why the direct acting antiviral properties of approved HBV-RT inhibitors (i.e. ETV and TDF), capsid
assembly modulators or entry inhibitors (like bulvertide) have little to no effect on circulating
- A detailed analysis of clinical effects of antisense / RNAi in HBV infection outlining the clear clinical
evidence for off target effects driving the HBsAg response in most patients.
- A detailed analysis of NAPs, outlining the remaining milestones required for ease of use in all
patients, regardless of liver disease or co-infection status.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical
data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the
development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further
information about Replicor please visit our website at www.replicor.com.